Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3847878 | 0.97 | TSHR (0.54) | TSHRCYP3A4MAPTCYP2C9RAB9A | |
| SCHEMBL3847871 | 0.97 | TSHR (0.54) | TSHRCYP3A4MAPTCYP2C9RAB9A | |
| SCHEMBL3600148 | 0.88 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL3845188 | 0.88 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL3600152 | 0.88 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL11253251 | 0.81 | ALDH1A1 (0.52) | CYP3A4CYP2C9RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4387495 | 0.81 | KDM4E (0.51) | TSHRMAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL15743850 | 0.81 | SMN1; SMN2 (0.48) | RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL8290690 | 0.81 | SMN1; SMN2 (0.48) | RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL9377286 | 0.79 | SMN1; SMN2 (0.47) | RAB9AALDH1A1SMN1; SMN2HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281845-A1 | ORGANIC COMPOUNDS | XIAP, BAX, MCL1 | TSHR 4844/4885CYP3A4 2815/4885MAPT 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.